论文部分内容阅读
目的观察Ph+成人急性淋巴细胞白血病应用伊马替尼联合化疗治疗的临床效果。方法选取平顶山市第一人民医院于2010年6月至2012年6月收治的18例Ph+成人急性淋巴细胞白血病患者为观察组,进行伊马替尼联合化疗治疗,患者临床症状完全缓解后交替应用伊马替尼与化疗治疗;另选同期化疗治疗的18例Ph+成人急性淋巴细胞白血病患者为对照组,观察比较其治疗效果。结果治疗结束后观察组完全缓解14例,部分缓解3例,未缓解1例,有效率为94.4%;对照组完全缓解5例,部分缓解6例,未缓解7例,有效率为61.1%,两组有效率比较差异有统计学意义(P<0.05)。观察组联合治疗过程中骨髓抑制4例,感染5例,对应处理后不良反应消失,对照组骨髓抑制6例,感染6例,两组不良反应比较差异无统计学意义(P>0.05),两组患者均无严重性出血及死亡病例。结论 Ph+成人急性淋巴细胞白血病患者应用伊马替尼联合化疗治疗有着良好的治疗效果,可以在临床上广泛推广。
Objective To observe the clinical effect of imatinib combined with chemotherapy on Ph + adult acute lymphoblastic leukemia. Methods 18 patients with Ph + adult acute lymphoblastic leukemia admitted to the First People’s Hospital of Pingdingshan from June 2010 to June 2012 were selected as the observation group and treated with imatinib combined with chemotherapy. The patients were treated with alternation of clinical symptoms after complete remission Imatinib and chemotherapy; the other 18 cases of Ph + adult acute lymphoblastic leukemia treated with concurrent chemotherapy as control group, the treatment effect was observed and compared. Results After the treatment, 14 cases were completely relieved in the observation group, 3 cases partially relieved and 1 case unresponsive, the effective rate was 94.4%. In the control group, 5 cases were completely relieved, 6 cases partially relieved, and 7 cases were not relieved. The effective rate was 61.1% The difference between the two groups was statistically significant (P <0.05). There were 4 cases of myelosuppression and 5 cases of infection in the observation group. There were 6 cases of myelosuppression and 6 cases of infection in the control group. There was no significant difference in adverse reactions between the two groups (P> 0.05) None of the patients had severe bleeding or death. Conclusion Ph + adult acute lymphoblastic leukemia patients with imatinib combined with chemotherapy have a good therapeutic effect, which can be widely popularized in clinic.